BioSpace News Archive

Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million . Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca’s biologics therapeutic

Immune Regulation Limited (“Immune Regulation”), a US and UK based clinical stage biotechnology company, today announced the closing of a Series B funding round led by Boston based Morningside Ventures (“Morningside”), alongside existing shareholders including London based 24Haymarket.

Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar + Mekinist alone

PerkinElmer Launches Solus Listeria monocytogenes ELISA Assay for Testing Across Food and Environmental Samples Solution Receives AOAC ® PTM SM Certification

The Fertility Partners (“TFP”) announced today that it has partnered with leading genetic testing laboratory Sequence46 in Los Angeles, California . This investment significantly expands the comprehensive services offered by its Canada -wide network of fertility clinics in the pursuit of global best IVF clinical outcomes and

A new study released today in the National Kidney Foundation’s American Journal of Kidney Diseases (AJKD) shows that the drug canagliflozin reduces the risk of adverse cardiovascular and kidney outcomes in people with type 2 diabetes

Spineology Inc. , an innovator in anatomy-conserving surgery, is excited to announce the FDA grant of its proprietary Spineology Interbody Fusion System, now called the OptiMesh Expandable Interbody Fusion System. The grant follows the successful completion of the SCOUT (Spineology Clinical Outcomes Trial) Investigational Device Exemption (IDE) trial. OptiMe

Trinity Life Sciences, a leader in global life sciences solutions, introduces Trinity EvidenceFirst™, a high-value subscription service that allows biopharmaceutical companies to take advantage of real-world insights like never before.

OnKure, Inc. , a leader in discovery and development of next generation histone deacetylase (HDAC) inhibitors, entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to support the clinical proof of concept study for MEKTOVI® (binimetinib) in combination with OKI-179, a highly potent and tolerable Class I HDAC inhibitor currently in Phase I for the treatment of NRAS melanoma.

Sept. 21, 2020 15:15 UTC Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV) Results published in Nature Biomedical Engineering demonstrate potential of Qihan’s genome editing platform to cr